WO2003101382A3 - Compounds useful in the treatment of anthrax and inhibiting lethal factor - Google Patents

Compounds useful in the treatment of anthrax and inhibiting lethal factor Download PDF

Info

Publication number
WO2003101382A3
WO2003101382A3 PCT/US2003/016336 US0316336W WO03101382A3 WO 2003101382 A3 WO2003101382 A3 WO 2003101382A3 US 0316336 W US0316336 W US 0316336W WO 03101382 A3 WO03101382 A3 WO 03101382A3
Authority
WO
WIPO (PCT)
Prior art keywords
anthrax
treatment
lethal factor
compounds useful
formula
Prior art date
Application number
PCT/US2003/016336
Other languages
French (fr)
Other versions
WO2003101382A2 (en
Inventor
Yusheng Xiong
Kevin Chapman
Suresh Singh
Jian Guo
Arthur A Patchett
Original Assignee
Merck & Co Inc
Yusheng Xiong
Kevin Chapman
Suresh Singh
Jian Guo
Arthur A Patchett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29711965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003101382(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/509,972 priority Critical patent/US7504425B2/en
Priority to IL16525903A priority patent/IL165259A0/en
Priority to BRPI0311136-9A priority patent/BR0311136A/en
Priority to SI200331591T priority patent/SI1511472T1/en
Priority to KR1020047019250A priority patent/KR100701811B1/en
Priority to JP2004508740A priority patent/JP4002927B2/en
Priority to AU2003239599A priority patent/AU2003239599B8/en
Priority to DK03734152T priority patent/DK1511472T3/en
Priority to EP03734152A priority patent/EP1511472B1/en
Application filed by Merck & Co Inc, Yusheng Xiong, Kevin Chapman, Suresh Singh, Jian Guo, Arthur A Patchett filed Critical Merck & Co Inc
Priority to MXPA04011767A priority patent/MXPA04011767A/en
Priority to CA2487727A priority patent/CA2487727C/en
Priority to NZ536189A priority patent/NZ536189A/en
Priority to DE60327432T priority patent/DE60327432D1/en
Priority to UA20041210878A priority patent/UA76059C2/en
Priority to AT03734152T priority patent/ATE429909T1/en
Publication of WO2003101382A2 publication Critical patent/WO2003101382A2/en
Publication of WO2003101382A3 publication Critical patent/WO2003101382A3/en
Priority to IS7517A priority patent/IS7517A/en
Priority to IL165259A priority patent/IL165259A/en
Priority to HR20041138A priority patent/HRP20041138A2/en
Priority to NO20045630A priority patent/NO329290B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

This invention relates to compounds of formula (I), and a method for treating anthrax or inhibiting lethal factor by administrating a composition containing a compound of formula (I) and a pharmaceutically acceptable carrier. This invention further relates to the use of the compounds of formula (I) to treat other conditions related to an anthrax infection.
PCT/US2003/016336 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor WO2003101382A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
MXPA04011767A MXPA04011767A (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor.
CA2487727A CA2487727C (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor
IL16525903A IL165259A0 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthraxa and inhibiting lethal factor
SI200331591T SI1511472T1 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor
KR1020047019250A KR100701811B1 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor
JP2004508740A JP4002927B2 (en) 2002-05-29 2003-05-23 Compounds useful for anthrax treatment and lethal factor inhibition
AU2003239599A AU2003239599B8 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor
DK03734152T DK1511472T3 (en) 2002-05-29 2003-05-23 Useful compounds for the treatment of Anthrax and inhibition of lethal factor
NZ536189A NZ536189A (en) 2002-05-29 2003-05-23 Methylphenylsulfonyl amide derivative compounds useful in the treatment of anthrax and inhibiting lethal factor
US10/509,972 US7504425B2 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor
AT03734152T ATE429909T1 (en) 2002-05-29 2003-05-23 USEFUL COMPOUNDS FOR THE TREATMENT OF ANTHRAX AND INHIBITION OF LETAL FACTOR
BRPI0311136-9A BR0311136A (en) 2002-05-29 2003-05-23 compound or a pharmaceutically acceptable salt, enanciomer, diastereomer or ester in vivo or mixture thereof, composition, and method for inhibiting the lethal factor (lf) activity released from bacteria in a mammal
EP03734152A EP1511472B1 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor
DE60327432T DE60327432D1 (en) 2002-05-29 2003-05-23 USEFUL COMPOUNDS FOR THE TREATMENT OF ANTHRAX AND INHIBITION OF THE LETAL FACTOR
UA20041210878A UA76059C2 (en) 2002-05-29 2003-05-23 Compounds used for treating anthrax or inhibiting lethal factor
IS7517A IS7517A (en) 2002-05-29 2004-10-28 Compounds used in the treatment of anthrax and prevent lethal effects
IL165259A IL165259A (en) 2002-05-29 2004-11-16 Compounds useful in the treatment of anthrax and inhibiting lethal factor
HR20041138A HRP20041138A2 (en) 2002-05-29 2004-11-26 Compounds useful in the treatment of anthrax and inhibiting lethal factor
NO20045630A NO329290B1 (en) 2002-05-29 2004-12-23 Compounds for treating anthrax and lethal factor inhibition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38399602P 2002-05-29 2002-05-29
US60/383,996 2002-05-29

Publications (2)

Publication Number Publication Date
WO2003101382A2 WO2003101382A2 (en) 2003-12-11
WO2003101382A3 true WO2003101382A3 (en) 2004-07-29

Family

ID=29711965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016336 WO2003101382A2 (en) 2002-05-29 2003-05-23 Compounds useful in the treatment of anthrax and inhibiting lethal factor

Country Status (28)

Country Link
US (1) US7504425B2 (en)
EP (1) EP1511472B1 (en)
JP (1) JP4002927B2 (en)
KR (1) KR100701811B1 (en)
CN (1) CN100475206C (en)
AT (1) ATE429909T1 (en)
AU (1) AU2003239599B8 (en)
BR (1) BR0311136A (en)
CA (1) CA2487727C (en)
CY (1) CY1109245T1 (en)
DE (1) DE60327432D1 (en)
DK (1) DK1511472T3 (en)
EC (1) ECSP045452A (en)
ES (1) ES2323527T3 (en)
HR (1) HRP20041138A2 (en)
IL (2) IL165259A0 (en)
IS (1) IS7517A (en)
MA (1) MA27257A1 (en)
MX (1) MXPA04011767A (en)
NO (1) NO329290B1 (en)
NZ (1) NZ536189A (en)
PL (1) PL374117A1 (en)
PT (1) PT1511472E (en)
RU (1) RU2289575C2 (en)
SI (1) SI1511472T1 (en)
UA (1) UA76059C2 (en)
WO (1) WO2003101382A2 (en)
ZA (1) ZA200408650B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165259A0 (en) 2002-05-29 2005-12-18 Merck & Co Inc Compounds useful in the treatment of anthraxa and inhibiting lethal factor
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US7579487B2 (en) * 2004-05-11 2009-08-25 Merck & Co., Inc. Process for making N-sulfonated-amino acid derivatives
ITFI20040174A1 (en) * 2004-08-03 2004-11-03 Protera S R L ARYTHOLPHONAMIDIC DERIVATIVES OF HYDROXAMIC ACID WITH INHIBITORY ACTION OF METALLOPROTEINASE
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
BRPI0709677A2 (en) * 2006-03-29 2011-07-19 Novartis Ag selective hydroxamate-based mmp inhibitors
WO2008094592A1 (en) 2007-02-01 2008-08-07 Panthera Biopharna, Llc Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning
US7807720B2 (en) 2007-02-01 2010-10-05 Panthera Biopharma, Llc Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning
US7879911B2 (en) * 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
US8119692B2 (en) 2007-04-02 2012-02-21 Panthera Biopharma Llc Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning
JP5539864B2 (en) * 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド Antibacterial agent
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CN101503475B (en) * 2009-03-12 2013-06-19 中国人民解放军军事医学科学院生物工程研究所 Fusion protein of anthrax lethal factor domain (LFn) and anthrax edema factor domain (EFn) and use thereof
WO2013170165A1 (en) 2012-05-10 2013-11-14 Achaogen, Inc. Antibacterial agents
CN111377849A (en) * 2018-12-28 2020-07-07 中国人民解放军军事科学院军事医学研究院 Compound, pharmaceutically acceptable salt thereof and medical application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018754A1 (en) * 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK165665C (en) 1984-10-15 1993-06-14 Sankyo Co PHARMACEUTICALS CONTAINING A PENEM OR CARBAPENEMANTIBIOTIC AND AN AMINO ACID DRIVE
DE3778857D1 (en) 1986-11-14 1992-06-11 Takasago Perfumery Co Ltd CATALYTIC PRODUCTION OF OPTICALLY ACTIVE CARBONIC ACIDS.
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5591631A (en) 1993-02-12 1997-01-07 The United States Of America As Represented By The Department Of Health And Human Services Anthrax toxin fusion proteins, nucleic acid encoding same
EP0845987A4 (en) 1995-08-08 2000-05-24 Fibrogen Inc C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen
DE69624536T2 (en) 1995-08-08 2003-06-05 Ono Pharmaceutical Co Hydroxamic acid derivatives can be used to inhibit gelatinase
SK282995B6 (en) 1996-01-23 2003-01-09 Shionogi And Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing same
CA2242416C (en) 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
JP2001503400A (en) 1996-10-22 2001-03-13 ファルマシア・アンド・アップジョン・カンパニー Α-Aminosulfonylhydroxamic acids as matrix metalloproteinase inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
JPH10204059A (en) 1997-01-22 1998-08-04 Ono Pharmaceut Co Ltd Phenylsulfonamide derivative
ZA98376B (en) 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
CA2282399A1 (en) 1997-03-04 1998-09-11 Monsanto Company Thioaryl sulfonamide hydroxamic acid compounds
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
JPH1135557A (en) 1997-07-17 1999-02-09 Ono Pharmaceut Co Ltd Phenylsulfonamide derivative
ID24105A (en) 1997-07-22 2000-07-06 Shionogi & Co COMPOSITION TO TREAT OR PREVENT GLOMERULOPATHY
EP1009737A2 (en) 1997-07-31 2000-06-21 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
PL341379A1 (en) 1997-11-14 2001-04-09 Searle & Co Aromatic sulphone substituted hydroxamic acid as inhibitor of metalloprotease
CA2318145C (en) 1998-02-04 2009-10-27 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JPH11246527A (en) 1998-03-02 1999-09-14 Shionogi & Co Ltd Mmp-8 inhibitor
US6485925B1 (en) 1998-04-01 2002-11-26 The United States Of America As Represented By The Department Of Health And Human Services Anthrax lethal factor is a MAPK kinase protease
KR20010042412A (en) 1998-04-03 2001-05-25 가와무라 요시부미 Sulfonamide derivatives
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
JP2003520940A (en) 1998-05-12 2003-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド Modification of molecular interaction sites of RNA and other biomolecules
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
FR2798291B1 (en) 1999-09-10 2005-01-14 Pasteur Institut IMMUNOGENIC ACELLULAR COMPOSITIONS AND VACCINE ACELLULAR COMPOSITIONS AGAINST BACILLUS ANTHRACIS
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
KR100440501B1 (en) * 2000-03-16 2004-07-15 주성엔지니어링(주) Method for forming a gate oxide layer of a semiconductor device
DE10014063A1 (en) 2000-03-22 2001-09-27 Kaltenbach & Voigt Medical or dental treatment chair or a headrest for such a treatment chair
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
PT1216707E (en) 2000-12-22 2005-06-30 Pasteur Institut NEW THERAPEUTIC UTILIZATIONS FOR A SMR-1-PEPTIDEO
PT1373262E (en) 2001-03-14 2010-07-26 Novartis Ag Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors
US7282580B2 (en) 2001-03-29 2007-10-16 Council Of Scientific And Industrial Research Protein molecule useful for inhibition of anthrax toxin
JP4219810B2 (en) 2001-10-26 2009-02-04 塩野義製薬株式会社 Sulfonamide derivatives having MMP inhibitory action
US7763451B2 (en) 2001-11-09 2010-07-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing Bacillus anthracis protective antigen for use in vaccines
AU2002346724B2 (en) 2001-12-14 2009-04-30 Exelixis, Inc. Human ADAM-10 inhibitors
US6927068B2 (en) 2002-01-30 2005-08-09 The United States Of America As Represented By The Secretary Of The Navy Rapid and non-invasive method to evaluate immunization status of a patient
US20040006040A1 (en) 2002-02-14 2004-01-08 Pyro Pharmaceuticals, Inc. Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor
WO2003073066A2 (en) 2002-02-25 2003-09-04 Merck & Co., Inc. Reagents and methods for assaying bacillus anthracis lethal factor protease
US20030224403A1 (en) 2002-02-27 2003-12-04 Popov Serguei G. Lethal toxin cytopathogenicity and novel approaches to anthrax treatment
IL165259A0 (en) 2002-05-29 2005-12-18 Merck & Co Inc Compounds useful in the treatment of anthraxa and inhibiting lethal factor
US6803379B2 (en) 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
WO2004011449A2 (en) 2002-07-25 2004-02-05 Wilex Ag Method for the production of phenylalanine derivatives
US20040138103A1 (en) 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
IL155111A0 (en) 2003-03-27 2003-10-31 Yerachmiel Yori Applebaum Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
WO2005037826A1 (en) 2003-10-17 2005-04-28 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
US7871790B2 (en) 2004-03-02 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Anthrax bioassays and methods of treating and diagnosing anthrax infection
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
US7579487B2 (en) 2004-05-11 2009-08-25 Merck & Co., Inc. Process for making N-sulfonated-amino acid derivatives
WO2006073514A2 (en) 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1998018754A1 (en) * 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BECKER D.P. ET AL.: "Alpha-amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 11, 2001, pages 2719 - 2725, XP002977848 *
CLEMENTS J.M. ET AL.: "Antimicrobial activities and characterization of novel inhibitors of LpxC", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 46, no. 6, June 2002 (2002-06-01), pages 1793 - 1799, XP002977849 *

Also Published As

Publication number Publication date
IL165259A0 (en) 2005-12-18
KR20050004250A (en) 2005-01-12
NO329290B1 (en) 2010-09-27
JP4002927B2 (en) 2007-11-07
NZ536189A (en) 2007-08-31
EP1511472B1 (en) 2009-04-29
KR100701811B1 (en) 2007-04-02
AU2003239599A1 (en) 2003-12-19
MA27257A1 (en) 2005-03-01
MXPA04011767A (en) 2005-03-31
US7504425B2 (en) 2009-03-17
EP1511472A2 (en) 2005-03-09
HRP20041138A2 (en) 2005-04-30
JP2005534643A (en) 2005-11-17
NO20045630L (en) 2005-02-10
BR0311136A (en) 2007-04-27
ATE429909T1 (en) 2009-05-15
AU2003239599B2 (en) 2008-07-17
DE60327432D1 (en) 2009-06-10
IL165259A (en) 2011-02-28
PL374117A1 (en) 2005-10-03
WO2003101382A2 (en) 2003-12-11
UA76059C2 (en) 2006-06-15
AU2003239599B8 (en) 2008-08-14
EP1511472A4 (en) 2006-09-27
RU2004138595A (en) 2005-06-10
US20050148629A1 (en) 2005-07-07
ES2323527T3 (en) 2009-07-20
IS7517A (en) 2004-10-28
CN1655773A (en) 2005-08-17
CN100475206C (en) 2009-04-08
CA2487727C (en) 2011-08-09
DK1511472T3 (en) 2009-08-24
PT1511472E (en) 2009-07-24
CA2487727A1 (en) 2003-12-11
SI1511472T1 (en) 2009-08-31
ECSP045452A (en) 2005-01-28
ZA200408650B (en) 2006-07-26
CY1109245T1 (en) 2014-07-02
RU2289575C2 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
CY1109245T1 (en) UNIONS USEFUL IN CARBON TREATMENT AND SUSPENSION OF DEATH FACTOR
MXPA04012965A (en) Viral inhibitors.
PL374191A1 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
HK1085675A1 (en) Anticancer compounds
NO20055766L (en) Positive modulators of nicotine acetylcholine receptors
MXPA05004621A (en) Anilinopyrazole derivatives useful for the treatment of diabetes.
WO2004011477A3 (en) 6,11-4-carbon bridged ketolides
MXPA04006041A (en) Pyridoquinoxaline antivirals.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
MXPA05010020A (en) Oxamide derivatives useful as raf-kinase inhibitors.
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2005027856A3 (en) Inhibitors of anthrax lethal factor
WO2007001839A3 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
TW200503672A (en) 2-aminobenzoyl derivatives
TW200505872A (en) Hepatitis C virus inhibitors
SE0302853D0 (en) Chemical compounds
RS20050738A (en) Pharmaceutical combination for the treatment of s pasticity and/or pain
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
AU2003267751A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
MY158057A (en) Viral inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200401206

Country of ref document: VN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501785

Country of ref document: PH

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10509972

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004/08650

Country of ref document: ZA

Ref document number: 200408650

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 536189

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003239599

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 165259

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2648/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: P20041138A

Country of ref document: HR

Ref document number: 1020047019250

Country of ref document: KR

Ref document number: 20038120437

Country of ref document: CN

Ref document number: 2487727

Country of ref document: CA

Ref document number: 2004508740

Country of ref document: JP

Ref document number: 374117

Country of ref document: PL

Ref document number: PA/a/2004/011767

Country of ref document: MX

Ref document number: 2003734152

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004138595

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020047019250

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003734152

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0311136

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2003239599

Country of ref document: AU

Date of ref document: 20030523

Kind code of ref document: B